TREATMENT OF OSTEOPOROSIS AND METABOLIC BONE DISORDERS WITH NITRIC OXIDE SUBSTRATE AND/OR DONORS

Abstract: Primary and secondary osteoporosis in a female or a male mammal in any age treated by administering thereto a nitric oxide synthase substrate, a nitric oxide donor or both, optionally; in further combination with one or more of an estrogen, a progestin, a bisphosphonate, an anabolic steroid, testosterone, a flavinid, vitamin D analogue or a calcitonin. Nitric oxide substrate or donor also can be combined with one or more of the other medication acting on bone, such as bisphosphonate, calcitonin, fluoride, androgen, vitamin D analogue, and other novel therapeutic agents. Either nitric oxide donor or substrate by itself or in combination with other medications as described above can be used in both males and females, for prevention and treatment of osteopenia or osteoporosis, and other metabolic bone disorders.

Description: DESCRIPTION TREATMENT OF OSTEOPOROSIS AND METABOLIC BONE DISORDERS WITH NITRIC OXIDE SUBSTRATE AND/OR DONORS BACKGROUND OF THE INVENTION This invention relates to a new method for treatment of osteoporosis and bone mineral disorders and to prevent bone loss, fractures, urogenital discomfort, and other conditions associated with the reduction in ovarian function in middle-aged women, with a nitric oxide synthase substrate (L-arginine), a nitric oxide donor, or both, alone or in combination with other drugs such as bisphosphonate, calcitonin, anabolic steroids, an estrogen and/or a progestin. Same compounds are also useful in men to decrease bone turnover and hence prevention and treatment of osteoporosis and for treatment of other metabolic bone disorders. It is now well known, that hormone replacement therapy, such as estrogen treatment, improves or reverses the adverse effects ofthe cessation of sex steroid secretion by the ovaries during menopause. Estrogens have also been shown to prevent bone loss and improve a variety of functions including mood and psychological well-being in postmenopausal women. Estrogens have been shown to effect arterial tone and this may help to explain the reduction in hot flushes and decrease the cardiovascular mobility and mortality in postmenopausal women with estrogen replacement therapy. Unopposed estrogen therapy in postmenopausal women has been associated with endometrial hyperplasia and endometrial cancer. Many studies have shown that the addition of progesterone to estrogen replacement therapy decreases the risk of endometrial cancer and even reverses endometrial hyperplasia. However, progestins are not without untoward side effects. Progestins may oppose the beneficial effects of estrogens on the cardiovascular system by inducing an adverse lipid profile in circulation. Progesterone may also counteract the beneficial effects of estrogen on vascular walls. Moreover, irregular or withdrawal bleedings are common with combined estrogen-progestin therapy. The current hormone replacement therapy (HRT) employs combinations of estrogen and progestins as in the case of most contraceptives. A significant proportion of postmenopausal women due to either medical (i.e., breast cancer) or social reasons (i.e., bleeding) cannot, or will not take estrogen (or hormone replacement therapy). In these women nitric oxide donor therapy is a suitable alternative treatment. One ofthe most exciting recent advances in biology and medicine is the discovery that nitric oxide which is produced by endothelial cells (as one ofthe endothelial derived relaxing factors) and that it is involved in the regulation of vascular tone, platelet aggregation, neurotransmission and immune activation in a favorable fashion (Furchgott and Zawaszki, 1980; Moncada, Palmer and Higgs, 1991 ; Ignarro, 1991). Nitric oxide is an important mediator of relaxation ofthe vascular smooth muscle (Moncada, Palmer and Higgs, 1991), was formerly known as EDRF (endothelin-derived relaxing factor) (Furchgott and Zawaszki, 1980; Moncada, Palmer and Higgs, 1991). Nitric oxide is synthesized by the oxidative deamination of a guanidine nitrogen of L-arginine by at least different isoforms of a flavin-containing enzyme, nitric oxide synthase (Moncada, Palmer and Higgs, 1991). Synthesis of nitric oxide has been shown to be competitively inhibited by analogues of L-arginine; N^- nitro-L-arginine methyl ester (L-NAME), NG-monoethyl-L-arginine (LMMA), N- iminoethyl-L-arnithine (L-NIO), L-monomethyl-L-arginine (L-NNMA) and L-N^- methylarginine (LNMA) and Nw-nitro-L-arginine (L-NA). Nitric oxide elevates levels of cGMP (1, 3, 5-cyclic guanosine monophosphate) within the vascular smooth muscle to produce relaxation and to reduce blood vessels tone (Moncada, Palmer and Higgs, 1991 ). Nitric oxide is also produced by macrophages and other immune cells. Nitric oxide binds to heme molecules and activates soluble guanylate cyclase (Ignarro, 1991 ) to increase the intracellular content of cGMP. It has long been recognized that nitrovasodilators, such as nitroprusside and nitroglycerine, inhibit vascular smooth muscle contractility to produce relaxation or to reduce vascular tone. These agents have been used since the late 1800's as vasodilators. However, only recently has the mechanism of action of these compounds been realized. Nitrovasodilators are now classified as nitric oxide donors because they are metabolized at the sites of interest to release nitric oxide (Moncada, Palmer and Higgs, 1991). The long-term use of nitrovasodilators may be regarded as substitution or a replacement therapy for a failing physiological mechanism. Nitric oxide is also synthesized within the bone by osteoblast cells in response to cytokines (Hukkanenm, et al, 1995). We have demonstrated that nitric oxide donors such as nitroglycerine, (i.e., osteoblast cells), spermine-NO, and DETA-NO increase the proliferation of bone-forming cells and therefore acts as an anabolic agent in the bone. Furthermore, for the first time, we recently demonstrated that nitroglycerin can prevent bone loss associated with ovariectomy and corticosteroid-induced bone loss. There is a substantial body of evidence from animal experiments that a deficiency in nitric oxide contributes to the pathogenesis of several diseases including hypertension, atherosclerosis and diabetes (Moncada, Palmer and Higgs, 1991) and toxemia of pregnancy (Yallampalli et al, 1993). There are many recent studies showing that the inhibition of nitric oxide synthase dramatically increases blood pressure. For example, the inhibition of nitric oxide synthesis with L-NNMA, L-NA or L-NAME leads to elevation of blood pressure and suggests that reduction of NO may contribute to the pathogenesis of hypertension (Moncada and Palmer, 1992). Furthermore, L-NAME-treatment potentiates the pressor responses to angiotensin, blunting ofthe release of nitric oxide by umbilical vessels (Pinto et al, 1991 ). The physiological decrease in blood pressure in pregnant spontaneous hypertensive rats was also shown to depend on endothelial derived nitric oxide (Ahokas, Merces and Sibal, 1991). Additionally, infusion of L-NA increases blood-pressure in pregnant rats and potentiates responses to vasopressors (Molnar and Hertelendy, 1992). These studies suggest that impaired nitric oxide synthesis may be an important mechanism in the etiology of several cardiovascular dysfunctions. Nitric oxide synthesis and nitric oxide effector system (cGMP-dependent relaxation mechanism) are thought to be regulated by steroid hormones. There is an increase in cardiovascular diseases in women following menopause and these might be related to the decrease in sex steroids and thereby an alteration in nitric oxide. Female steroid hormones have been shown to modulate endothelium-dependent relaxation of vascular smooth muscle via nitric oxide. Estradiol treatment of rats causes increased nitric oxide production by vascular tissues, whereas progesterone counteracts this phenomenon (Miller and Van Houtte, 1991 ). It is well known that pregnancy is associated with an increase in cardiac output and a decrease in the resistance of virtually all the vascular beds in the body, although the mechanism of this phenomenon is not known. It is possible that this may be associated with changes in nitric oxide production or an increase in the responsiveness to the potent vasodilator calcitonin gene-related peptide, as a result of elevated steroid hormone levels. One important observation with regard to the above mechanism is that antiprogestins elevate blood pressure in animals and they produce hot flushes in humans, both males and females. The hot flushes may be mediated by the inadequate sex-steroid action on the release of nitric oxide. Hot flushes are a primary symptom in menopausal and postmenopausal women and they are relieved by both estrogen and progesterone. This invention is also applicable to both primary and secondary osteoporosis in both females and males. In the female, the method of choice of treatment of primary osteoporosis is estrogen replacement therapy and in the case of male, the method of choice of treatment of primary osteoporosis is androgen replacement therapy with or without bisphosphonate. In both sexes for the secondary osteoporosis, the underlying causative factors are numerous, including medication-induced osteoporosis (e.g., corticosteroids, antiepileptics, anticoagulants, thyroxine), immunosuppressant agents used in prevention of graft rejection and other disorders (cyclosporin and transplant- induced osteoporosis), malignancies (e.g., multiple myeloma), immobilization-induced bone loss and other conditions of bone loss, including osteoporosis secondary to lack of gravity and weightlessness. One aspect of the invention to provide a method for the prevention and treatment of primary and secondary osteoporosis including medication induced- osteoporosis (i.e. corticosteroid -induced osteoporosis) and other metabolic bone disorders with a nitric oxide-producing substrate and/or donor. It is another object to provide such a method in which a progestational agent is used in combination with a nitric oxide substrate and/or donor for the prevention and treatment of osteoporosis and other metabolic bone disorders. It is a further object to provide a method for the prevention and treatment of osteoporosis and other metabolic bone disorders using an estrogenic agent (or selective anti-estrogens) in combination with a nitric oxide substrate and/or donor. It is another object to provide a method for prevention and treatment of osteoporosis and other metabolic bone disorders using a combination of an estrogenic agent and progestational agent with a nitric oxide substrate and/or donor. Another object is to provide a method of prevention and treatment of primary and secondary osteoporosis and other metabolic bone disorders in males and females using a combination of a bisphosphonate agent with a nitric oxide substrate and/or donor. Another object is to provide a method of prevention and treatment of primary and secondary osteoporosis and other metabolic bone disorders in males and females using a combination of vitamin D, or vitamin D analogue agent with nitric oxide substrate and or donor. Another object is to provide a method of prevention and treatment of male primary and secondary osteoporosis and other metabolic bone disorders using a nitric oxide-producing substrate and/or donor. A further object is the provision of phaπnaceutical compositions useful in practicing the methods of this invention. Other objects will be apparent to those skilled in the art to which this invention pertains. Another object is to provide a method of prevention and treatment of male primary and secondary osteoporosis and other metabolic bone disorders using nitric oxide substrate and/or donor, alone or in combination with androgens, anabolic steroids, vitamin D analogue, fluoride, or a bisphosphonate. SUMMARY OF THE INVENTION An important embodiment this invention relates to a method of treating osteoporosis or other metabolic bone disorders in a menopausal or postmenopausal female and male. This embodiment comprises administering to a female manifesting the symptoms thereof one or both of a nitric oxide donor, or any other compound releasing nitric oxide, alone or in further combination with one or more of an estrogen, a progestin, bisphosphonate or calcitonin in amounts effective to ameliorate the osteoporosis. The amount ofthe estrogen used is bioequivalent to approximately 2 mg per day of estradiol and the amount ofthe progestational agent administered is bioequivalent to 50 - 300 mg of injected progesterone. The amount ofthe nitric oxide synthase substrate, nitric oxide donor or both is effective to, respectively, either raise the blood level of circulating L-arginine in a pregnant female to whom the composition is administered to at least about 10 - 50 μmol above the normally 50 - 100 μmol circulating levels or raise nitric oxide donor levels to about 1 - 1000 nmolar (nanomolar). This invention also relates to use of L-arginine or any nitric oxide donor compounds in prevention and treatment of primary and secondary osteoporosis in both sexes, including medication-induced osteoporosis (i.e. corticosteroid-induced osteoporosis), transplant-induced osteoporosis, and other metabolic bone disorders. L- arginine is the only acknowledged substrate of nitric oxide synthase but any analogous substrates behaving in a similar manner are viewed as equivalent. However, there are a large number of nitric donor compounds which can be used in this invention, the preferred donor being nitroglycerin. In a product aspect, this invention relates to a pharmaceutical composition comprising at least one of the nitric oxide synthase substrate and/or a nitric oxide donor, alone or in further combination with one or more of a estrogen and/or progestin, bisphosphonate, calcitonin, or vitamin D analogue. The amount ofthe estrogen is bioequivalent to about 2 mg of estradiol. The amount of progestin is bioequivalent to 50 - 300 mg of injected progesterone. The amount of L-arginine per unit dosage is effective to either raise blood level of circulating L-arginine to at least about 10-50 μmol above the normally 50-100 μmol circulating levels. The nitric oxide donor levels are enough to raise the nitric oxide levels to a physiologically effective level or about 1 to 1000 nM. The dose of bisphosphonates, calcitonin and vitamin D analogue depends on their individual potency and the particular patient being treated. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 illustrates the percentage changes of bone mineral density in the lumbar spine in female rats over a 6 weeks treatment period in various treatment groups: OVX = ovariectomy, E2 = estrogen treated, LN = L-NAME treated, NG = nitroglycerine treated. Values are mean ± SEM for 5 animals per group. Comparisons were made against ovariectomized rats (reference, OVX control) *P<0.05, **P<0.02 . FIG. 2 illustrates the mean femur weights (mg) over a 6 week treatment period in various treatment groups: OVX = ovariectomy, E2 = estrogen treated, LN = L- NAME treated, NG = nitroglycerine treated. Values are mean ± SEM of right and left femurs from 5 animals per group. Comparisons were made against ovariectomized rats (reference, OVX control) *P<0.05, **P<0.02 . FIG. 3 illustrates the percentage changes of body weight over a 6 week treatment period in various treatment groups: OVX = ovariectomy, E2 = estrogen treated, LN = L-NAME treated, NG = nitroglycerine treated. Values are mean ± SEM for 5 animals per group. Comparisons were made against sham operated rats (control) *P<0.01. FIG. 4 illustrates the percentage changes of bone mineral density (BMD) over the 6-week treatment period in older male rats in various treatment groups: control, CS = corticosteroids, L-NAME = NG-nitro-L-arginine methyl ester, NG = nitroglycerine, and CS + NG = the combination of prednisolone and NG. Values are mean ± SEM for 5 animals per group. Statistical comparisons were made against the control rats (ANOVA). *P<0.05. FIG. 5 illustrates the femur weights (g) over the 6-week treatment period in various treatment groups: control, CS = corticosteroids, L-NAME = NG-nitro-L- arginine methyl ester, NG = nitroglycerine, and CS + NG = the combination of prednisolone and NG. Values are mean ± SEM of right and left femurs from 5 animals per group. Statistical comparisons were made against control rats (ANOVA). *P<0.05. FIG. 6 illustrates the trabecular bone volume (%TBV) in A) distal femoral, and B) proximal tibial metaphysis. Treatment groups: control, CS = corticosteroids, L- NAME = NG-nitro-L-arginine methyl ester, NG = nitroglycerine, and CS + NG = the combination of prednisolone and NG. Data is expressed as percentage of TBV measured at the end ofthe 6-week treatment period. Values are means ± SEM from 3 animals per group. Statistical comparisons were made against the control group (ANOVA) *P<0.05. FIG. 7 illustrates the mid-shaft cortical bone area (mm ) in A) femur, and B) tibia. Treatment groups: control, CS = corticosteroids, L-NAME = NG-nitro-L- arginine methyl ester, NG = nitroglycerine, and CS + NG = the combination of prednisolone and NG. Data is expressed as percentage of TBV measured at the end of the 6-week treatment period. Values are means ± SEM from 3 animals per group. Statistical comparisons were made against the control group (ANOVA) *P<0.05. A = distal femoral metaphysis; B = proximal tibial metaphysis. FIG. 8 illustrates the levels of serum osteocalcin (ng/ml) in: control, CS = corticosteroids, L-NAME = NG-nitro-L-arginine methyl ester, NG = nitroglycerine, and CS + NG = the combination of prednisolone and NG. There were no statistical differences (ANOVA) between the groups. FIG. 9 illustrates the effects of increasing the serum testosterone levels (ng/ml) in response to nitroglycerin. Control (placebo-treated), rats treated with corticosteroid (CS), L-NAME = NG-nitro-L-arginine methyl ester, nitroglycerine (NG), and the combination of prednisolone and NG (CS + NG). Values are means ± SEM from 5 animals per group. Statistical comparisons were made against the control group (ANOVA) *P<0.05. FIG. 10 illustrates the dose-dependent effect on bone mineral density over a 12- week treatment period in 24-week old female rats with various treatments: control sham, ovariectomy (OVX-placebo), estrogen therapy (OVX-E2), NG = nitroglycerine cream administered one-time, two-time, and three-times a day. Values are mean ± SEM for 5 animals per group. Statistical comparisons were made against the OVX rats. *P<0.05. FIG. 1 1 illustrates the dose-dependent effects of nitroglycerin on mean femur weight in 24-week ovariectomized female rats, control sham, ovariectomy (OVX- placebo), estrogen therapy (OVX-E2), NG = nitroglycerine cream administered one- time, two-time, and three-times a day. Values are mean ± SEM for 5 animals per group. Statistical comparisons were made against the OVX rats. * <0.05. FIG. 12 illustrates the biphasic dose-dependent effects of nitric oxide donor DETA-NO on osteoblast cell proliferation (anabolic effect). FIG. 13 illustrates the biphasic dose-dependent effects of cyclic GMP on osteoblast cell proliferation (anabolic effect). FIG. 14 illustrates the biphasic dose-dependent effects of nitric oxide donor spemine-NO on polyclonal marrow cells (precursors for osteoblast cells (anabolic effect). FIG. 15 illustrates the effects on the bone mineral density of placebo and nitroglycerin alone in comparison to combined treatments with niroglycerine plus estrogen, nitroglycerin plus progestrone, nitroglycerin plus a bisphosphonate, nitroglycerin plus vitamin D, nitroglycerine plus salmon calcitonin. DESCRIPTION OF PREFERRED EMBODIMENTS The methods of this invention to treat osteoporosis and other bone mineral disorders in a menopausal/postmenopausal mammal and in men, preferably a human, who is manifesting the signs and/or symptoms or both (i.e. treatment of osteoporosis), or who is a high risk candidate (i.e., prevention of osteoporosis) for doing so, e.g., as determined by appropriate clinical conditions. Because these conditions of bone loss and other metabolic bone diseases in both sexes are produced by or aggravated by subnormal nitric oxide synthesis, both nitric oxide synthase substrate and NO donors, (e.g., L-arginine, and nitric oxide donors, e.g., sodium nitroprusside, nitroprusside, nitroglycerine, glycerin trinitrate, SIN-1, isosorbid mononitrate and isosorbid dinitrate) are useful for ameliorating the symptoms thereof and, in one aspect ofthe method of this invention, a combination of both or a combination with other established medications are employed. In the case of female, for both primary and secondary osteoporosis, an added effect is achieved when the nitric oxide synthase substrate and/or nitric oxide donor is administered concurrently with an estrogen and/or progestational agent, a bisphosphonate, calcitonin, or a vitamin D analogue. Thus, the method aspect of this invention and the pharmaceutical composition aspect of this invention employs a nitric oxide donor and/or a nitric oxide synthase substrate alone or together with an estrogen and/or a progestin, progesterone or norgestrel, or other agents that affect bone metabolism including bisphosphonates, calcitonin, vitamin D metabolites and fluoride. In the case of male, for both primary and secondary osteoporosis, an added effect is achieved when the nitric oxide substrate and/or nitric oxide donor is administered concurrently with an androgen, bisphosphonate, calcitonin, or a vitamin D analogue. Thus, the method aspect of this invention and the pharmacological composition aspect of this invention employs a nitric oxide donor and a nitric oxide synthase substrate alone or together with an androgen or other agents that affect bone metabolism including bisphosphonates, calcitonin, vitamin D analogues, fluoride, and anabolic steroids. Examples or combinations of active agents which can be administered concurrently with a nitric oxide substrate and/or nitric oxide donor are estrogens and progestins (see below). Examples of dosage ranges of typical NO synthase substrates and NO-donors (per os) are: Total dose L-Arginine 500 mg - lOg p.o. Sodium Nitroprusside range 500 - 2000 ug/kg/day Nitroglycerine 0.5 - 10 mg Isosorbid mononitrate 10 - 100 mg Isosorbid dinitrate 10 - 100 mg The following are typical oral dosage ranges of active agents ofthe estrogen and progestin with the nitric oxide synthase substrate or donor: Estrogens: a daily dose bioequivalent to about 1 to 2 mg per day, e.g., Premarin, Prempro (Wyeth-Ayerst), 0.325-2.5 mg/day, estradiol valerate, 50-200 μg/day transdermally, vaginal estradiol creams, 1.25 mg/day and vaginal estradiol rings, 0.2 mg/day, percutaneously applied estrogen such as oestrogel (1-3 mg of 17β estradiol/day). Progestins: A daily dose bioequivalent to 50 - 300 mg of progesterone/day, e.g., an injectable suspension of medroxyprogesterone acetate to provide a weekly dose of thereof of 100 - 1000 mg or tablets or dragees providing an oral dose thereof of 2.5 - 10 mg/day, an injectable solution of hydroxyprogesterone caproate which provides a weekly dose of 250 - 500 mg; tablets, capsules or dragees of northindrone acetate which provide a daily dose of 5 - 20 mg. Other examples of estrogens and progestins are listed below: Oral "natural" estrogens used in hormone replacement therapy currently available are: Product Composition Dose (mg per day) Climaval (Sandoz) Estradiol valerate 1 or 2 Progynova (Schering) Estradiol valerate 1 or 2 Harmogen (Abbott) Piperazine oestrone sulfate 1.5 or 2.5 Hormonin (Shire) Estradiol 0.6 + Estrone + Estriol Estrogel Estradiol 1 - 3 Premarin (Wyeth-Ayerst) Conjugated equine 0.625 or 1.25 or 2.5 Estrogens Commercially available combination calendar packs or hormone replacement therapy. Product Generic composition Estrapak Estradiol 50 μg per day (28 days, 8 patches) Prempak-C + Trisequens Norethisterone acetate 1 mg per day ( 12 days) Trisequens forte conjugated equine oestrogens 0.625 mg per day (28 days) Cycloprogynova + Norgestrel 0.15 mg per day (12 days) conjugated equine oestrogens 1.25 mg per day (28 days) + Norgestrel 0.15 mg per day (12 days) Estradiol 2 mg per day + oestriol 1 mg per day (22 days) + Norethisterone acetate 1 mg per day (10 days) Estradiol 2 mg per day + oestriol 0.5 mg per day (6 days) Estradiol 4 mg per day + oestriol 2 mg per day (22 days) + Norethisterone acetate 1 mg per day (10 days) Estradiol 1 mg per day + oestriol 0.5 mg per day (6 days) Estradiol valerate 1 mg per day (21 days) + Levonorgestrel 0.25 mg per day (10 days) Estradiol valerate 2 mg per day (21 days) + Levonorgestrel 0.5 mg per day (10 days) Prempro or premphase Premarin plus provera Daily doses of progestogens taken for 12 days per month in patients receiving oral or transdermal estrogens. Norethisterone 0.7 - 2.5 mg per day Medroxyprogesterone acetate 10 mg per day Norgestrel 150 μg per day Dydrogesterone 10 - 20 mg per day Bisphosphonates: Any ofthe available pharmaceutical preparations of bisphosphonates, i.e. Disodium etidronate 5-10 mg/kg BWt for 14 days in every 90 days, Alendronate 10 mg, once daily and other newer preparations such as Pamidronate, Clodronate, Residronate, or Ibandronate, and others. Calcitonin: Any ofthe available pharmaceutical preparations of calcitonin, i.e. salmon, eel, or human calcitonins, dosage range 10-200 i.u.. daily, parenteral or nasal, pulmonary, or other routes. Anabolic steroids: Any of the available pharmaceutical preparations of anabolic steroids, i.e. Nondrolone decorate 50 mg. 1/M injection every 3 weeks or equivalent drugs. Androgens: Any ofthe available pharmaceutical preparations of Testosterone (100 mg, 1/M, monthly) or its analogs. Fluoride: Any ofthe available pharmaceutical preparations of fluoride, i.e. Sodium fluoride, 10-50 mg, once daily. Vitamin D and Vitamin D analogues: Any ofthe available pharmaceutical preparations of vitamin D (e.g. 400-1000 units, once daily) or bio-equivalent doses of vitamin D metabolites and analogues. The pharmacologically active agents employed in this invention can be administered in admixture with conventional excipients, i.e., pharmaceutically acceptable liquid, semi-liquid or solid organic or inorganic carriers suitable, e.g., for parenteral or enteral application and which do not deleteriously react with the active compound in admixture therewith. Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohols, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, vicious paraffin, perfume oil, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose, polyvinyl pyrrolidone, etc. The pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances and the like which do not deleteriously react with the active compounds. For parenteral application, particularly suitable are solutions, preferably oily or aqeous solutions, as well as suspensions, emulsions, depot perforations or implants, including suppositories, creams, ointments, transdermal patches and inhaled forms including aerosols. In a preferred aspect, the composition of this invention is adapted for ingestion. For enteral application, particularly suitable are unit dosage forms, e.g., tablets, dragees or capsules having talc and/or a carbohydrate carrier or binder ofthe like, the carrier preferable being lactose and/or corn starch and/or potato starch; particulate solids, e.g., granules; and liquids and semi-liquids, e.g., syrups and elixirs ofthe like, wherein a sweetened vehicle is employed. Sustained release compositions can be formulated including those wherein the active compound is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc. Suitable for oral administration are, inter alia, tablets, dragees, capsules, pills, granules, suspensions and solutions. Each unit dose, e.g., each tablespoon of liquid or each tablet, or dragee contains, for example, 0.1 - 1000 mg of each active agent. Solutions for parenteral administration contain, for example, 0.01 - 1% of each active agent in an aqueous or alcoholic solution. The nitric oxide synthase substrate and/or NO donor can be administered as an admixture with agents described above and any other optional active agent of as a separate unit dosage form, either simultaneously therewith or at different times during the day from each other. The combination of active agents is preferably administered at least once daily (unless administered in a dosage form which delivers the active agents continuously) and sometimes several times daily, e.g., in 2 to 6 divided doses. The typical dose is about 0.5 to 1000 mg of each active agent, although some less active agents, e.g., L- Arginine, require much higher oral dosages, e.g., 500 to 10,000 mg, and others, e.g., sodium nitroprusside, require lower doses, e.g., 500 - 2000 ug kg/day. Doses for nitroglycerine typically are orally 2.5 mg 2 x daily; sublingually, 0.8 mg 1 - 4 x daily; and transdermally via patch or cream, 0.2 - 0.4 mg hr. Since the LD 50 dosages of most ofthese active agents is known in the prior art, a lower dosage regimen can be initiated and the dosage increased until a positive effect is achieved or a higher dosage regimen can initially be employed, e.g., in a crisis situation, and the dosages regulated downward as relief from the symptoms is achieved. Combinations of agents can be employed either continuously or sequentially. In humans, L-arginine, estradiol, and progesterone (or bioequivalent of another progestin) should be given in a ratio which produces blood plasma levels of about 50 - 200 nmolar L-arginine, 500 to 1000 nmolar of estradiol, and 30 - 100 nmolar progesterone. The invention will be further understood with reference to the following figures: FIG. 1 illustrates the percentage changes of bone mineral density (BMD) 6 weeks after each therapy as determined by dual energy x-ray absorptiometric bone scan (DXA) of vertebrae. OVX = ovariectomy, E2 = estrogen treated, LN = L-NAME treated, NG = nitroglycerine treated. Values are mean ± SEM for 5 animals per group. Comparisons were made against ovariectomized rats (reference, OVX control) *P < 0.05, **P < 0.02. For between group comparison the changes of BMD were calculated from the baseline measurements and expressed as percentages. As expected, the increase in BMD over the 6 week period in OVX rats was substantially lower (P < 0.02) than control sham-operated animals. Supplementation with E2 completely reversed the effects of OVX on BMD, and the BMD was similar to that seen in sham- operated rats (i.e., control group). The addition of L-NAME was no further detrimental to the reduction in bone mass in OVX rats. However, the supplementation of E2 in the presence of L-NAME completely failed to increase the BMD, in comparison to the OVX rats that received E2 replacement. On the other hand, OVX rats that received NO donor managed to increase their BMD, similar to the rats who received E2 replacement. The BMD in these two groups were similar to that in sham OVX rats, and the combination of E2 and NO donor (NG) was not additive. FIG. 2 shows the weights of femurs in rats following various treatments for 6 weeks. OVX = ovariectomy, E2 = estrogen treated, LN = L-NAME treated, NG = nitroglycerine treated. Values are mean ± SEM of right and left femurs from 5 animals per group. Comparisons were made against ovariectomized rats (reference, OVX control) * P < 0.05, **P < 0.02. Femoral weights in OVX rats were substantially lower (P < 0.02) compared to sham-operated rats. The OVX-induced decrease in femoral weight was reversed by E2 (P < 0.02), and also by NO donor treatment (P < 0.05). Again as with BMD, the E2 effect to increase bone weight was blocked by L- NAME. NO donor alone restored the bone weights in OVX rats to the levels of E2 treated OVX and sham-operated (control) rats. FIG. 3: Percentage changes of body weight over 6 weeks treatment period in various treatment groups: OVX = ovariectomy, E2 = estrogen treated, LN = L-NAME treated, NG = nitroglycerine treated. Values are mean ± SEM for 5 animals per group. Comparisons were made against sham-operated rats (control) * P < 0.01. As expected OVX increased the body weight (due to the increase in total body fat, P < 0.01), and this was prevented by E2 replacement alone or combination of estrogen with nitroglycerine. There was a tendency to lose some weight in L-NAME treated rats, but this was not statistically different to that observed with the sham-operated as well as estrogen treated rats. The weight of rats receiving NG alone had a similar increase in weight to that observed with OVX rats. Surgical or natural menopause in women leads to both cortical and trabecular bone loss (S. J. Wimalawansa. 1993V Osteoporosis induced by OVX in rats has been widely used as a model of postmenopausal osteoporosis (P. N. Kalu. 1991 ) and has been validated as a clinically relevant model of human postmenopausal bone loss rWronski et al. 1993 . Our data demonstrate that, treatment with NO protects against the OVX-induced bone loss in adult female rats, as determined by DXA BMD measurements and bone weights. Our study shows that OVX for 6 weeks in 12 week old female rats decreased the increment of BMD (P < 0.02), and this was prevented with either E2 replacement or administration of a NO donor. Moreover, it is likely that the E2-induced increase in BMD is dependent upon NO generation, since L-NAME completely obliterated the effects of estradiol. These studies indicate that exogenous NO can reverse the bone loss in estradiol-deficit animals and that estradiol-induced increase in BMD may be NO dependent. FIG. 4 illustrates the percentage changes of bone mineral density (i.e., changes from the baseline) 6 weeks after therapy. The control group showed no change in bone mineral density [from 0.2986 (basal) to 0.2984 (at 6-week); -0.1 1 % ± 1.75, NS), while the glucocorticoid-treated group showed a substantial decrease (0.2971 to 0.2688; - 9.50 ± 3.34, PO.05). Supplementation with NG prevented steroid-induced bone loss (0.2916 to 0.2896; -2.15 % ± 2.32, NS) which was also statistically not different from the controls. Treatment of control rats with nitroglycerin alone had no effect on the bone mineral density (0.2893 to 0.2882; -0.36 % ± 2.72, NS). Treatment with L- NAME, a nitric oxide synthase inhibitor led to a -14.3% ± 2.3 (0.2885 to 0.2461 ; P<0.05) decrease in bone mineral density. FIG. 5 shows the weights of femurs in rats following various treatments for 6 weeks. Femoral weights in corticosteroid-treated rats (1.09 ± 0.01 g) were significantly lower compared to control rats (1.17 ±0.03, PO.05). As in the case of BMD, a NO donor alone did not have a measurable effect on the femoral weight (1.16 ± 0.04). However, the concomitant administration of nitroglycerin with prednisolone prevented the expected loss of femur weight (1.13 ± 0.02). The L-NAME treated group had a mean femur weight of 1.05 ± 0.04 which is significantly lower than the control group (P<0.05). FIG. 6 shows that corticosteroid as well as L-NAME therapies produced a shaφ reduction in the percentages of trabecular bone volume (TBV%) in the distal femoral and proximal tibial metaphysis (50% to 70% reduction, P<0.05). However, concomitant therapy of prednisolone with NG abolished this loss of TBV in both proximal tibia and in distal femur. The rats who received NG alone showed about a 20% reduction of TBV, which is statistically not significant from the control group. FIG. 7 shows the changes of cortical area (mm ) ofthe femur and tibia ofthe 5 treatment groups. The treatments with corticosteroid and L-NAME both produced a significant reduction ofthe cortical areas (-50% reduction) in the distal femoral and proximal tibial metaphysis (P<0.05). As in the case of trabecular bone, concomitant administration of NG with prednisolone prevented the decrease of cortical areas in both distal femur and proximal tibia. The rats who received NG alone showed no measurable effect on both sites measured. FIG. 8 shows serum osteocalcin levels in 4 groups of rats. Osteocalcin levels were decreased in both corticosteroid- and L-NAME treated rats. The levels of serum osteocalcin measured in the group treated with NG alone, or combined therapy with prednisolone and nitroglycerin were similar to the levels observed in the control group. FIG. 9 shows the serum testosterone levels in these 5 groups of rats. The levels of serum testosterone in both the glucocorticoid-treated and L-NAME-treated rats were significantly lower than in the control rats (P<0.05%), while nitroglycerine alone had no effect on the circulatory levels of testosterone. However, concomitant therapy of NO donor with prednisolone tend to an increase ofthe circulating testosterone levels. FIG. 10 shows the dose-dependant effect of nitroglycerin on bone mineral density. Once daily therapy seems to have the best effect on the bone mineral density. FIG. 1 1 shows the dose-dependant effect of nitroglycerin on femur weight Once daily therapy again seems to have the best effect on the bone weights. FIG. 12 to FIG. 14 shows the dose-dependent effects of various nitric oxide donor therapies on bone forming osteoblast cells and osteoblast precursor cells. The effects are clearly biphasic and lower more physiological doses have the beneficial effects on osteoblast cell replication and hence bone formation. FIG. 15 shows the comparative effects of various combination therapies of nitroglycerin with currently available drugs used for the treatment of osteoporosis in comparison to a placebo and nitroglycerin therapy alone. Although nitroglycerin alone is very effective in increasing the bone mineral density, combined therapies have an additive effects when administered together with a nitric oxide donor. Our data clearly demonstrated that treatment with nitric oxide donor protects against both estrogen-deficient and corticosteroid- induced bone loss, as determined by DXA bone density measurements, bone weights, and bone histomorphometry. We demonstrated that a 6- weeks of treatment with glucocorticoid in adult male rats resulted in a -9.5% decrease ofthe BMD and a -7.8% decrease in femoral weight (P<0.05), and these decreases were prevented by the administration of a nitric oxide donor nitroglycerin. In addition, there is a substantial decrease in TBV in corticosteroid treated rats compared with controls (P<0.05), and rats treated with nitroglycerin, and this too was prevented with nitroglycerin therapy. Furthermore, serum osteocalcin levels were higher in corticosteroid-treated rats treated with nitroglycerin, suggesting that nitroglycerin may influence bone formation (FIG. 8). The current study indicates that exogenously administered nitric oxide can prevent the bone loss associated with corticosteroid therapy. The fact that nitric oxide donor (e.g., nitroglycerin), when administered topically, can prevent bone loss in this animal model indicates the usefulness of nitric oxide donors as a therapy (i.e., a simple, safe, and economical, as well as effective mode of delivery of nitric oxide) for preventing corticosteroid-induced osteoporosis. L-NAME, an inhibitor of nitric oxide synthase enzyme (NOS) decreased the BMD (- 15.2%) and femoral weights (-10.2%). Therefore, it is likely that constitutive production of nitric oxide is important in regulating osteoclastic activity in both males and females, and this NOS activity may depend upon sex steroid hormones. The levels of testosterone in the glucocorticoid-treated rats were lower than in the control rats in the present study (FIG. 9) and this decrease in serum testosterone levels may at least in part contribute to the decreased bone formation observed in the corticosteroid-treated rats. These decreased serum testosterone levels could further decrease the basal production of nitric oxide, and thus adversely affect the bone metabolism. Therefore, in glucocorticoid-treated individuals, as a substitute for hormone replacement therapy (i.e., replacement with estrogen in females, or parenterally administered androgens in males), one may be able to administer nitric oxide donor to prevent the decrease of bone mineral density and to preserve skeletal strength. In glucocorticoid-induced osteoporosis, there is a predominant suppression of bone formation with some degree of increase in bone resorption. Low and moderate concentrations of nitric oxide, on the other hand, have been shown to decrease osteoclast-mediated bone resorption. Therefore, the preventative effect of nitric oxide donor on glucocorticoid-induced bone loss demonstrated herein is mediated through stimulation of bone formation, in addition to a decrease in bone resorption. Although specific mechanisms of action of nitric oxide in bone are incompletely understood, in addition to a direct effect of nitric oxide on bone cells, the beneficial effects may have been due to the increase of serum testosterone levels. In this study we demonstrate for the first time that an adequate supply of nitric oxide donors to bone via general circulation can attenuate the glucocorticoid-induced bone loss in rats. These studies indicate that exogenously administered nitric oxide has therapeutic value in preventing the bone loss accompanying estrogen deficiency and drug-induced bone loss. These studies emphasize the potential importance of nitric oxide in regulating bone mineral metabolism. The fact that nitroglycerine, when administered topically can prevent bone loss suggests the usefulness of nitric oxide donors as therapy (e.g., a simple and effective mode of delivery) for preventing bone loss in postmenopausal women. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative ofthe disclosure in any way whatsoever. The entire disclosure of all applications, patents and publications, cited herein are hereby incorporated by reference. EXAMPLES Example 1 : Treatment of osteoporosis and other metabolic bone disorders To a nonpregnant human female (ca 45 years; 50 - 80 kg) displaying the signs of menopause or osteoporosis (primary and secondary) and/or other metabolic bone disorders, or to a human male displaying signs of osteoporosis and/or other metabolic bone disorders, administer L-arginine initially with a dose range of 0.5 to 20g of L- arginine per os daily in three divided doses followed by a daily dose of 0.5 to 5g of L- arginine. Example 2: Treatment of osteoporosis and other metabolic bone disorders To a female or male comparable to Example 1 , administer daily 5-25 mg of nitroglycerine. Example 3: Treatment of osteoporosis and other metabolic bone disorders To a female comparable to Example 1, administer 5-25 mg of nitroglycerin or daily 0.5 to 20 g of L-arginine in combination with estrogen (e.g. estradiol valerate) 1 - 2 mg daily. Example 4: Treatment of osteoporosis and other metabolic bone disorders To a female comparable to Example 1 , administer daily 5-25 mg nitroglycerine or 0.5- 20 g of L-arginine in combination with a progestin (e.g. norgestrel) 150 μg per day. Example 5: Treatment of osteoporosis and other metabolic bone disorders To a male comparable to Example 1 , administer daily 0.5 to 20g of L-arginine in combination with suitable depot preparation of an androgen. Example 6: Treatment of osteoporosis and other metabolic bone disorders To a male or a female, comparable to Example 1, administer daily 5-25 mg nitroglycerine with a suitable depot preparation of an androgen. Example 7: Treatment of osteoporosis and other metabolic bone disorders To a female comparable to Example 1, administer L-arginine 0.5 to 20g daily and/or a nitric oxide donor (e.g. nitroglycerine, 5-25 mg) daily with or without one of the following, an estrogen (e.g. estradiol valerate) 1 - 2 mg daily, or a progestin (e.g. norgestrel, at 150 μg per day), anabolic steroid or an androgen, respectively. The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants (bisphosphonate, calcitonin, anabolic steroids, fluoride) and/or operating conditions of this invention for those used in the preceding examples. From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims: CLAIMS 1. A method for prevention and treatment of primary and secondary osteoporosis and other metabolic bone disorders in a female or male human or other mammal which comprises administering to the susceptible or afflicted mammal an amount of at least one of nitric oxide synthase substrate, a nitric oxide donor effective to raise the blood level of circulating L-arginine to at least about 10-50 μmol above the normally 50-100 μmol circulating levels, or a nitric oxide donor in an amount producing a level of nitric oxide about bioequivalent to that produced by the elevated L-arginine levels. 2. The method of claim 1, where the mammal is female, further comprising administration of at least one of an estrogen and progestin. 3. The method of claim 1, where the mammal is male, further comprising administration of an androgen or an anabolic steroid. 4. The method of claim 1 further comprising administration of another agent affecting bone metabolism. 5. The method of claim 4 where the agent is at least one of a bisphosphonate. calcitonin, vitamin D metabolite, anabolic steroid, or fluoride. 6. The method of claim 1, wherein the mammal is a female human suffering from primary or secondary osteoporosis. 7. The method of claim 1 , wherein the mammal is a female human subject to hormone replacement therapy, or a candidate for hormone replacement therapy or for osteopenia osteoporosis therapy. 8. The method of claim 1 wherein the mammal is a male human having osteopenia, osteoporosis, or being a candidate for osteoporosis therapy. 9. The method of claim 1 , wherein the mammal is a human and L-arginine is administered thereto. 10. The method of claim 1, wherein the mammal is a human and a nitric oxide donor is administered thereto. 11. The method of claim 10, wherein the nitric oxide donor is sodium nitroprusside, nitrogylcerine, SIN-1, isosorbidmononitrate, isosorbiddinitrate, or any compound which can deliver or generate nitric oxide once administered. 12. The method of claim 1, wherein the nitric oxide donor is administered orally, via the skin, in aerosol form, or parenterally. 13. The method of claim 10 where the administration is transdermal, by inhalation, percutaneous, intravenous, intramuscular, subcutaneous, depot preparation, sublingual or rectal. 14. The method of claim 1, wherein the mammal is human female or male, and the L-arginine or nitric oxide donor is administered in combination with a calcium- containing compound. 15. The method of claim 1 , wherein the mammal is a human female or male, and the L-arginine or nitric oxide donor is administered in combination with vitamin D or vitamin D analogue with or without calcium supplements. 16. The method of claim 1 , wherein the mammal is a female and the nitric oxide synthase substrate or nitric oxide donor is administered in combination with an estrogen. 17. The method of claim 16, wherein the estrogen is estradiol valerate, conjugated equine estrogens, 17β estradiol, estrone, estriol or a similar compound. 18. The method of claim 16, where the estrogen is an estrogen analog, estrogen agonist, or an antiestrogen. 19. The method of claim 1 , wherein the mammal is a female and the nitric oxide synthase substrate or nitric oxide donor is administered in combination with a progestin. 20. The method of claim 19, wherein the progestin is progesterone, dyprogesterone, medroxyprogestereon, norethisterone, levonorgestrel, norgestrel or any similar compound. 21. The method of claim 19, where the progestin is a progestational compound or progestin analog. 22. The method of claim 2, wherein the mammal is a female human and the estrogen or progestin is administered continuously. 23. The method of claim 2, wherein the mammal is a female human and the estrogen or progestin is administered cyclically or sequentially. 24. The method of claim 1 , wherein the mammal is a human and the nitric oxide synthase substrate or nitric oxide donor is administered in combination with a bisphosphonate. 25. The method of claim 24, wherein the bisphosphonate is disodium etidronate, pamidronate, clodronate, residronate, alendronate, ibandronate, or a similar compound. 26. The method of claim 1 , wherein the mammal is a human and the nitric oxide synthase substrate or nitric acid donor is administered in combination with calcitonin. 27. The method of claim 26, wherein the calcitonin is salmon calcitonin, eel calcitonin, human calcitonin, or a calcitonin analog. 28. The method of claim 1, wherein the mammal is a human and the nitric oxide synthase substrate or nitric oxide donor is administered in combination with amylin (IAPP, DAP). 29. The method of claim 28, wherein the amylin for a sequence is based on human amylin, hybrid molecules or an amylin analogue. 30. The method of claim 1 , wherein the mammal is a human and the nitric oxide synthase substrate or nitric oxide donor is administered in combination with a fluoride salt. 31. The method of claim 30, wherein the fluoride salt is a rapid, slow or timed- release formulation of fluoride, with or without calcium. 32. The method of claim 1, wherein the mammal is a human and the nitric oxide synthase substrate or nitric oxide donor is administered in combination with an anabolic steroid. 33. The method of claim 32, wherein the anabolic steroid is nandrolone decanoate or a similar compound. 34. The method of claim 1, wherein the mammal is human and the nitric oxide synthase substrate or nitric oxide donor is administered in combination with natural or synthetic flavinoid. 35. The method of claim 14, the calcium is at a dose of from 50 mg to 4000 mg per day. 36. The method of claim 15, the vitamin D is at a dose of from 100-500 iu per day or an equivalent amount of vitamin D analogue. 37. The method of claim 5 wherein the mammal is a human and calcium, bisphosphonate, calcitonin. flavinoids, fluoride, vitamin D. or anabolic steroid is administered continuously. 38. The method of claim 5 wherein the mammal is a human and calcium, bisphosphonate, flavinoids, calcitonin, vitamin D, or fluoride is administered cyclically. 39. The method of claim 1 wherein the male mammal is a human and the nitric oxide synthase substrate or nitric oxide donor is administered in combination with an androgen. 40. The method of claim 39, wherein the androgen is testosterone or a similar compound. 41. The method of claim 3 wherein the mammal is a male human and the androgen or similar compound is administered continuously. 42. The method of claim 3, wherein the mammal is a male human and the androgen or a similar compound is administered cyclically. 43. A pharmaceutical composition comprising (a) at least one of L-arginine and a nitric oxide donor, and (b) at least one of, an estrogen, a progestin, a bisphosphonate, a calcitonin, a vitamin D analogue, a flavinoid, a fluoride, an anabolic steroid, an androgen, insulin-like growth factor, bone moφhogenic protein, transforming growth factor-β, growth hormone, or other metabolic agent. >Z 44. The composition of claim 43, wherein L-arginine is in an amount effective to raise blood level of circulating L-arginine to at least about 10-50 μmolar above normally circulating levels upon administration to a patient. 45. The composition of claim 43 wherein the nitric oxide donor is in an amount effective, upon administration to raise nitric oxide levels to about 1- 1000 nmolar. 46. The composition of claim 43, wherein the estrogen is in an amount equivalent to 1-2 mg of estradiol. 47. The composition of claim 43 wherein the progestin in an amount bioequivalent to 50-300 mg of injected progesterone. 48. The composition of claim 43 wherein bisphosphonate is in an amount bioequivalent to 2.5-20 mg/kg of disodium etidronate. 49. The composition of claim 43 wherein calcitonin is in an amount bioequivalent to 10-400 I.U. of human calcitonin. 50. The composition of claim 43 wherein fluoride is in an amount equivalent to 10- 50 mg of sodium fluoride. 51. The composition of claim 43 wherein anabolic steroid is in an amount equivalent to 50 mg of nandrolone decanoate, and androgens are in an amount equivalent to 100 mg of testosterone. 52. The composition according to claim 43, wherein L-arginine is present. 53. The composition according to claim 43, wherein a nitric oxide donor is present. 54. The composition according to claim 53, wherein the nitric oxide donor is sodium nitroprusside, nitroglycerin, glyceryltrinitrate, SlN-1, isosorbidmononitrate, isosorbiddinitrate, or other compound which can release, deliver or generate nitric oxide. 55. The composition according to claim 43, wherein the estrogen is natural or synthetic estrogen, estrogen agonist, or antiestrogen. 56. The composition according to claim 43, wherein the progestin is norgestrel, synthetic or natural progestogen. 57. The composition according to claim 43, wherein the bisphosphonate is disodium etidronate, pamidronate, clodronate, residronate. alandronate. ibandronate, or a similar group of compound. 58. The composition according to claim 43. wherein the calcitonin is human, salmon or eel calcitonin. 59. The composition according to claim 43, wherein the flavinoid is a natural or synthetic compound. 60. The composition according to claim 43, wherein the fluoride is sodium fluoride or a slow or timed-release formula fluoride preparation. 61. The composition according to claim 43, wherein vitamin D is parental form, 25 (OH) vitamin D, 1,25 (OH) 2 vitamin D, or a vitamin D metabolite or analogue. 62. The composition according to claim 43, wherein the anabolic steroid is nandrolone decanoate, or a similar anabolic compound. 63. The composition according to claim 43, wherein the androgen is testosterone. 64. The composition according to claim 43, wherein the insulin-like growth factor is IGF-I, IGF-II or their analogues or insulin-like growth factor binding proteins, or a combination of insulin-like growth factor and its binding protein. 65. The composition according to claim 43, wherein the transforming growth factor-β, its analogue, or genetically engineered products of transforming growth factor-β. 66. The composition according to claim 43, wherein the bone moφhogenic protein is a genetically engineered protein. 67. The composition according to claim 43, wherein the growth hormone is synthetic, natural, or genetically engineered. 68. The composition according to claim 43 includes a compound capable of increasing bone formation (i.e., having anabolic effects on the skeleton).

Inventors: WILAMAWANSA SUNIL J, YALLAMPALLI CHANDRASEKHAR, WILAMAWANSA, SUNIL, J., YALLAMPALLI, CHANDRASEKHAR
Applicants: UNIV TEXAS, WILAMAWANSA SUNIL J, YALLAMPALLI CHANDRASEKHAR, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, WILAMAWANSA, SUNIL, J., YALLAMPALLI, CHANDRASEKHAR
Application year: 1997
Main classification: A61K31
IPC codes: A61K31, A61K45